`
`1/,..
`
`If’/.1a//4
`
`am
`
`14MarI:h2000
`
`Rachid Berhamza, Ph. D.
`Helsinn Healthcare SA
`PO. Box 357
`5915 Pambio-Noranoo
`(Lugnno) Switznrland
`
`Subject:
`
`Palonoaeton Opportunity
`
`Dear Mr. Benhamza:
`
`I am writing in response to your inquiy to Andrew Gengos of 15 Fobniaw 2000 regarding he
`Palonosetron opportunity. After a comprehensive intamal review, we have omciuded that the program
`does not correspond with our current prlorues.
`
`our review of the data raised ooncernsover Palonosetront potenial oompealliva advantages with
`respect to present 5-HT3 products in terms of efficacy and ease of admiristralion lgwen its required IV
`adrnlnlstralion).
`in addiion, we feel the market polantia for a Palonoselmn pmducl may be limited by
`the crowded competitive arena of 5-HT3 products in acule emesis and the optimism forfuiure NK-1
`products in delayed ernesis.
`
`Thougw we have readied a decision notlo move forward atlhis tine, weweloome anythoughis ordala
`you feel would ham to clarify ou-thinking surrounding lhese issues.
`
`Asyou requested, I am ramming tho orighal confidential documents that you submitted to Chron h
`support of our evaluation.
`
`if you have any quations or would like lo discuss this further, you may contact meal 510.923.2747
`Thank you for the opportmlty to evaluate this program.
`
`Best Regards,
`
`/L
`
`Michael P. Smith
`Associate Director, Corporate Daveloprnent
`
`Enclcmros
`
`HIGHLY CONFIDENTIAL - OUTSIDE COUNSEL EYES ONLY
`
`HELSN0389668
`
`Page 1 of 1
`
`Dr. Reddy's Laboratories, Ltd., et al. v. Helsinn Healthcare S.A.
`Trial PGR2016-00007
`
`Helsinn Healthcare Exhibit 2058